FEBRUARY 02, 2023
Biophytis announces positive final results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19 COVA study met primary end point with 44% significant reduction in the risk of respiratory failure or early death. Filing for Early Access Programs to Sarconeos (BIO101) is being initated while preparing for Marketing Authorisation in Europe and…